These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38076677)

  • 1. 5-MeO-DMT for post-traumatic stress disorder: a real-world longitudinal case study.
    Ragnhildstveit A; Khan R; Seli P; Bass LC; August RJ; Kaiyo M; Barr N; Jackson LK; Gaffrey MS; Barsuglia JP; Averill LA
    Front Psychiatry; 2023; 14():1271152. PubMed ID: 38076677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infoveillance and Critical Analysis of the Systematically Reviewed Literature on Dimethyltryptamine and the "God Molecule".
    Al-Imam A; Motyka MA; Hoffmann B; Magowska A; Michalak M
    Pharmaceuticals (Basel); 2023 Jun; 16(6):. PubMed ID: 37375778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms.
    Uthaug MV; Lancelotta R; van Oorsouw K; Kuypers KPC; Mason N; Rak J; Šuláková A; Jurok R; Maryška M; Kuchař M; Páleníček T; Riba J; Ramaekers JG
    Psychopharmacology (Berl); 2019 Sep; 236(9):2653-2666. PubMed ID: 30982127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study.
    Barsuglia J; Davis AK; Palmer R; Lancelotta R; Windham-Herman AM; Peterson K; Polanco M; Grant R; Griffiths RR
    Front Psychol; 2018; 9():2459. PubMed ID: 30574112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption.
    Davis AK; Barsuglia JP; Lancelotta R; Grant RM; Renn E
    J Psychopharmacol; 2018 Jul; 32(7):779-792. PubMed ID: 29708042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder.
    Barsuglia JP; Polanco M; Palmer R; Malcolm BJ; Kelmendi B; Calvey T
    Prog Brain Res; 2018; 242():121-158. PubMed ID: 30471678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Qualitative and Quantitative Analysis of Tryptamines in the Poison of Incilius alvarius (Amphibia: Bufonidae).
    Schwelm HM; Zimmermann N; Scholl T; Penner J; Autret A; Auwärter V; Neukamm MA
    J Anal Toxicol; 2022 May; 46(5):540-548. PubMed ID: 33851996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers.
    Reckweg J; Mason NL; van Leeuwen C; Toennes SW; Terwey TH; Ramaekers JG
    Front Pharmacol; 2021; 12():760671. PubMed ID: 34912222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects.
    Lancelotta RL; Davis AK
    J Psychoactive Drugs; 2020; 52(3):273-281. PubMed ID: 32148190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety.
    Davis AK; So S; Lancelotta R; Barsuglia JP; Griffiths RR
    Am J Drug Alcohol Abuse; 2019; 45(2):161-169. PubMed ID: 30822141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?
    Dourron HM; Nichols CD; Simonsson O; Bradley M; Carhart-Harris R; Hendricks PS
    Psychopharmacology (Berl); 2023 Dec; ():. PubMed ID: 38072874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT).
    Reckweg JT; Uthaug MV; Szabo A; Davis AK; Lancelotta R; Mason NL; Ramaekers JG
    J Neurochem; 2022 Jul; 162(1):128-146. PubMed ID: 35149998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-
    Rucker JJ; Roberts C; Seynaeve M; Young AH; Suttle B; Yamamoto T; Ermakova AO; Dunbar F; Wiegand F
    J Psychopharmacol; 2024 Aug; 38(8):712-723. PubMed ID: 38616411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A narrative synthesis of research with 5-MeO-DMT.
    Ermakova AO; Dunbar F; Rucker J; Johnson MW
    J Psychopharmacol; 2022 Mar; 36(3):273-294. PubMed ID: 34666554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential of 5-methoxy-N,N-dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action.
    Tap SC
    Addict Biol; 2024 Apr; 29(4):e13386. PubMed ID: 38600715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine in human subjects: a systematic review of clinical trials.
    Kwaśny A; Wilkowska A; Cubała WJ
    Front Psychiatry; 2024; 15():1477996. PubMed ID: 39364380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "In vivo biosynthesis of N,N-dimethyltryptamine, 5-MeO-N,N-dimethyltryptamine, and bufotenine in E.coli".
    Friedberg LM; Sen AK; Nguyen Q; Tonucci GP; Hellwarth EB; Gibbons WJ; Jones JA
    Metab Eng; 2023 Jul; 78():61-71. PubMed ID: 37230161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico.
    Davis AK; Xin Y; Sepeda N; Averill LA
    Am J Drug Alcohol Abuse; 2023 Sep; 49(5):587-596. PubMed ID: 37734158
    [No Abstract]   [Full Text] [Related]  

  • 19. Serotonergic psychedelic 5-MeO-DMT alters plasticity-related gene expression and generates anxiolytic effects in stressed mice.
    Nogueira M; Ferreira Golbert DC; Menezes R; Nóbrega de Almeida R; Galvão-Coelho NL; Siroky AN; Lima TZ; Maia H; Leão KE; Leão RN
    Mol Psychiatry; 2024 Jul; ():. PubMed ID: 38969716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT(1A) and 5-HT(2A) receptors.
    Riga MS; Bortolozzi A; Campa L; Artigas F; Celada P
    Neuropharmacology; 2016 Feb; 101():370-8. PubMed ID: 26477571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.